SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Choice Institutional Equities Maintains Buy on Zydus Lifesciences

The brokerage maintains its positive view, citing a specialty and complex-products pipeline, and projects 17.2% revenue CAGR in FY26–29E.

ZYDUSLIFE

Related stories